A Comparison 24 Hour Intraocular Pressures Between Travoprost 0.004% and Timolol Gel 0.1% on Controlled Primary Open Angle Glaucoma
Article Sidebar
Submitted
January 30, 2016
Published
January 31, 2016
Abstract
Background: To compare 24 hours intraocular pressure (IOP) in patients controlled primary open angle glaucoma treated with timolol gel 0.1% versus travoprost 0.004%.
Method: 26 controlled primary open angle glaucoma patients were randomized to received travoprost 0.004% dosed in the evening or timolol gel 0.1% dosed in the morning. After 4 weeks of treatments 24 hours IOP curved was performed at 9 a.m until 6 a.m every 3 hours.
Result: The mean IOP of travoprost 0.004% group was 12.2±1.5 mmHg and timolol 0.1% group was 13.4±1.9 mmHg (p>0.05). The IOP fluctuation of travoprost 0.004% was 3.9±1.4 mmHg and timolol gel 0.1% was 5.9±1.4 mmHg (p<0.05). Peak IOP travoprost 0.004% was 14.3±1.7 mmHg and timolol gel 0.1 % was 16.8±1.7 mmHg (p<0.05). Travoprost 0.004% has lower IOP in almost each point measurement compare to timolol gel 0.1%.
Conclusion: Travoprost 0.004% has lower fluctuation, peak and mean IOP compare to timolol gel 0.1%.
Keywords: Primary open angle glaucoma, IOP fluctuation, peak IOP, travoprost 0.004%, timolol gel 0.1%
Full text article
Generated from XML file
References
Quigley H A, Broman A T. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmo. 2006;90:262-7.
Staff AAO. Glaucoma Basic and clinical science. San Fransisco; 2009-2010.
Kooner K.S. Clinical Pathways in Glaucoma. New York: Thieme New York; 2001.
Cook C, Foster P. Epidemiology of glaucoma whats new? Can J opthalmol. 2012;47:223-6.
Faiqoh M. Karakteristik pasien di divisi glaukoma poliklinik mata rscm tahun 2001-2010 Jakarta: universitas Indonesia; 2011
Leske M.C, Heijl A, Hussein M, Hyman L, Bengtsson B, komarof E. Factors for Glaucoma progression and the effect of treatment. The Early Manifest Glaucoma Trial. Arch Ophthalmol. 2003;121:48-56.
Chiselita D, Motoc I, Danielescu C. Daily and nightly fluctuation of intraocular pressure and blood pressure in glaucoma and non glaucoma patients. Oftalmologia. 2008;52:119-25.
Sihota R, Saxena R, Gogoi M, Sood A, Gulati V, Pandey M. A comparison of the circadian rhythm of intraocular pressure in primary chronic angle closure glaucoma, primary open angle glaucoma and normal eyes. Indian J Ophthalmol 2005;53:243-7.
Bello C M, Chauhan B C, NIicolela M T, Mccormick T A, Leblanc R. Intraocular Pressure and Progression of Glaucomatous Visual Field Loss. Am J Ophthalmol. 2000;129:302-8.
Rivera J L, Bell N P, Feldman R M. Risk factors for primary open angle glaucoma progression: what we know and what we need to know. Current Opinion in Ophthalmology. 2008;19:102-6.
AGIS I. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:429-40.
Asrani S, Zeimer R, Wilensky J, Gieser D. Large diurnal fluctuations in intraocular pressure are independent risk factor in patients with glaucoma. J Glaucoma. 2000;9:134-42.
Stewart WC CR, Hunt HH, . Factors associated with visual field loss in patients with advanced glaucomatous changes in the optic nerve head. Am J Ophthalmol. 1993;116:176-81.
Fellman RL SK, Ratlif M, Silver HL, Whitson JT. Comparison of Travoprost 0.0015% and 0.004% with Timolol 0.5% in Patients with Elevated Intraocular Pressure. Ophthalmology 2002;109:998-1008.
Konstas A.G.P, Mikropoulos D.G, Kaltsos K, Stewart W.C. 24-Hour Intraocular Pressure Control Obtained with Evening- versus Morning-Dosed Travoprost in Primary Open-Angle Glaucoma. Ophthalmology. 2006;113:446-50.
Stewart WC KA, Kruft B, Heather MM, Stewart JA. Meta-Analysis of 24-h Intraocular Pressure Fluctuation Studies and the Efficacy of Glaucoma Medicines. J Ocul pharmacol and ther. 2010;26:175-80.
Tamm E.R, Toris C, Crowston J, Sit A, Lim S, Lambrou G,. Basic science of intraocular pressure Amsterdam: Kugler Publications; 2007
Stampers R.L, Lieberman M.F, Drake M.V. Aqueous humor formation in Beckers shafers diagnosis and therapy of the glaucomas. 8 ed. china: Elsevier Inc.; 2009.
Nouri-Mahdavi K HD, Coleman A. Predictive factors for glaucomatous visual field progression in advanced glaucoma intervention study. ophthalmology. 2004;111:1627-35.
David R, Zangwill L, Briscoe D, Dagan M, Yagev R, Yassur Y. Diurnal intraocular pressure variations: an analysis of 690 diurnal curves. British Journal of Ophthalmology 1992;76:280-3.
Bagga H, John H.K. Liu J.H.K, Weinreb R.N. Intraocular pressure measurements throughout the 24 h. Curr Opin Ophthalmol. 2009;20:79-83.
Hara T, Hara T, Tsuru T. Increase of Peak Intraocular Pressure During Sleep in Reproduced Diurnal Changes by Posture. Arch Ophthalmol. 2006;124:165-8.
Doshi AB LJ, Weinreb RN. Circardian change in intraocular pressure. Berlin: Springer-Verlag; 2009.
Barkana Y AS, Liebmann J, Tello C, Robert Ritch R. Clinical utility of intraocular pressure monitoring outside of normal office hours in patients with glaucoma. Arch Ophthalmol. 2006;124:793-7.
De Moraes C.G.V, Juthani V.J, Liebmann J.M, Teng C.C, Tello C, Susanna Jr R, Ritch R. Risk Factors for Visual Field Progression in Treated Glaucoma. Arch Ophthalmol 2011;129:562-8.
Kenneth Schwartza K, Budenzb D. Current management of glaucoma. Curr Opin Ophthalmol. 2004;15:119-26.
Leske M.C, Heijl A, Hyman L, Bengtsson B, Dong L, Yang Z,. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology 2007;114:1965-72.
Khouri A.S, Lama P.J, Fecthner R.D. Glaucoma medical therapy principles and management. new york: Oxford university press; 2008.
Zimmermant T.J, Bauman J.D, Hetherington J, . Side effects of timolol. Surv of ophthalmology. 1983;28 243-9.
Chiang, Ho J I, Chen J.C. Pharmacokinetics and intraocular pressure lowering effect of timolol preparations in rabbit eyes. Journal of ocular pharmacology and therapeutics 1996;12:471-80.
Dickstein K, Aarsland T. Comparison of the effects of aqueous and gellan ophthalmic timolol on peak exercise performance in middle aged men. Am J Ophthalmol 1996;121:367-71.
Hellberg MR, Verney L, Salle VL, Mclaughlin MA,. Sharif NA, Desantis L, Dean TR,. Zinke PW. Preclinical efficacy of Travoprost, a potent and selective FP prostaglandin receptor agonist. J Ocul pharmacol and ther 2001;17.
Toris CB, Zhan G, Fan S, Dickerson JE, Landry TA, Bergamini MV, Camras CB. Effects of Travoprost on Aqueous Humor Dynamics in Patients With Elevated Intraocular Pressure. J Glaucoma. 2007;16:189-95.
Toris CB. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol 2008;53:107-20.
Netland PA. Travoprost Study Group: Response to travoprost in black and non black patients with open angle glaucoma or ocular hypertension. Adv Ther. 2003;20:149-63.
Goldberg I, Cunha-Vaz JC, Jakobsen JE, Nordmann JP, Trost E, Sullivan K. Comparison of topical Travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. Journal of Glaucoma. 2001;10:414-22.
Stewart WC, Stewart JA, Nelson LA, Kruft B. Mean Standart Deviation for common glaucoma treatments. Acta Ophthalmol. 2009;87(1):112-4.
Lichter PR. Expectations from clinical trials results of the early manifest glaucoma trial. Arch Ophthalmol 2002;120:1371-2.
Martinez-Bello C CB, Nicolela MT. Intraocular pressure and progression of glaucomatous visual field loss. Am J Ophthalmol. 2000;129:302-8.
Medeiros F.A WRA, Zangwill L.M, Alencar L.M, Sample P.A, Vasile C, Bowd.C. Long-term Intraocular Pressure Fluctuations and Risk of Conversion from Ocular Hypertension to Glaucoma. Ophthalmology. 2008;115:934-40.
Caprioli J, Coleman. Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressure in the anvanced glaucoma intervention study. ophthalmology. 2008;115:1123-9.
Lee PP, Walt WJ, Rossenblatt LC, Siegartel LR, Stern LS. Association between intraocular pressure variation and glaucoma progression : data from a united states chart review. Am J Ophthalmol. 2007;144:901-7.
Nomura Y.Nakakura S. Effect of travoprost on 24-hour intraocular pressure in normal tension glaucoma. Clinical Opthalmology. 2010;4:643-7.
Dubiner HB., Noecker R,. Sustained intraocular pressure reduction throughout the day with travoprost ophthalmic solution 0.004%. Clinical Ophthalmology 2012;6:525-31.
Sit AJ, Weinreb NR, Jonathan G. Crowston GJ, Daniel F. Kripke DF, Liu JHK. Sustained effect of travoprost on diurnal and nocturnal intraocular pressure. Am J Ophthalmol. 2006;141:1131-3.
Larsson LI. Intraocular Pressure over 24 Hours after Repeated Administration of Latanoprost 0.005% or Timolol Gel-forming Solution 0.5% in Patients with Ocular Hypertension. ophthalmology. 2001;108:1439-44.
Konstas A.G.P, Mantziris DA, Cate EA, Stewart W.C. Effect timolol on the diurnal intraocular pressure in exfoliation and primary open angle glaucoma. Arch Ophthalmol. 1997;115:975-9.
Orzalesi N, Rossetti L, Invernizzi T, Bottoli A, Autelitano A. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sc. 2000;41:2566-73.
Konstas AGP, Quaranta L, Mikropoulos D.G,Nasr M.B, Russo A, Jaffee H.A,Stewart J, Stewart W.C. Peak intraocular pressure and glaucomatous progression in primary open-angle glaucoma. J Ocul Pharmacol Ther. 2012;28.
Wilensky JT, Gieser DK, Mori MT. Self tonometry to manage patients with glaucoma Am J Ophthalmol. 1987;105:1072-5.
Staff AAO. Glaucoma Basic and clinical science. San Fransisco; 2009-2010.
Kooner K.S. Clinical Pathways in Glaucoma. New York: Thieme New York; 2001.
Cook C, Foster P. Epidemiology of glaucoma whats new? Can J opthalmol. 2012;47:223-6.
Faiqoh M. Karakteristik pasien di divisi glaukoma poliklinik mata rscm tahun 2001-2010 Jakarta: universitas Indonesia; 2011
Leske M.C, Heijl A, Hussein M, Hyman L, Bengtsson B, komarof E. Factors for Glaucoma progression and the effect of treatment. The Early Manifest Glaucoma Trial. Arch Ophthalmol. 2003;121:48-56.
Chiselita D, Motoc I, Danielescu C. Daily and nightly fluctuation of intraocular pressure and blood pressure in glaucoma and non glaucoma patients. Oftalmologia. 2008;52:119-25.
Sihota R, Saxena R, Gogoi M, Sood A, Gulati V, Pandey M. A comparison of the circadian rhythm of intraocular pressure in primary chronic angle closure glaucoma, primary open angle glaucoma and normal eyes. Indian J Ophthalmol 2005;53:243-7.
Bello C M, Chauhan B C, NIicolela M T, Mccormick T A, Leblanc R. Intraocular Pressure and Progression of Glaucomatous Visual Field Loss. Am J Ophthalmol. 2000;129:302-8.
Rivera J L, Bell N P, Feldman R M. Risk factors for primary open angle glaucoma progression: what we know and what we need to know. Current Opinion in Ophthalmology. 2008;19:102-6.
AGIS I. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:429-40.
Asrani S, Zeimer R, Wilensky J, Gieser D. Large diurnal fluctuations in intraocular pressure are independent risk factor in patients with glaucoma. J Glaucoma. 2000;9:134-42.
Stewart WC CR, Hunt HH, . Factors associated with visual field loss in patients with advanced glaucomatous changes in the optic nerve head. Am J Ophthalmol. 1993;116:176-81.
Fellman RL SK, Ratlif M, Silver HL, Whitson JT. Comparison of Travoprost 0.0015% and 0.004% with Timolol 0.5% in Patients with Elevated Intraocular Pressure. Ophthalmology 2002;109:998-1008.
Konstas A.G.P, Mikropoulos D.G, Kaltsos K, Stewart W.C. 24-Hour Intraocular Pressure Control Obtained with Evening- versus Morning-Dosed Travoprost in Primary Open-Angle Glaucoma. Ophthalmology. 2006;113:446-50.
Stewart WC KA, Kruft B, Heather MM, Stewart JA. Meta-Analysis of 24-h Intraocular Pressure Fluctuation Studies and the Efficacy of Glaucoma Medicines. J Ocul pharmacol and ther. 2010;26:175-80.
Tamm E.R, Toris C, Crowston J, Sit A, Lim S, Lambrou G,. Basic science of intraocular pressure Amsterdam: Kugler Publications; 2007
Stampers R.L, Lieberman M.F, Drake M.V. Aqueous humor formation in Beckers shafers diagnosis and therapy of the glaucomas. 8 ed. china: Elsevier Inc.; 2009.
Nouri-Mahdavi K HD, Coleman A. Predictive factors for glaucomatous visual field progression in advanced glaucoma intervention study. ophthalmology. 2004;111:1627-35.
David R, Zangwill L, Briscoe D, Dagan M, Yagev R, Yassur Y. Diurnal intraocular pressure variations: an analysis of 690 diurnal curves. British Journal of Ophthalmology 1992;76:280-3.
Bagga H, John H.K. Liu J.H.K, Weinreb R.N. Intraocular pressure measurements throughout the 24 h. Curr Opin Ophthalmol. 2009;20:79-83.
Hara T, Hara T, Tsuru T. Increase of Peak Intraocular Pressure During Sleep in Reproduced Diurnal Changes by Posture. Arch Ophthalmol. 2006;124:165-8.
Doshi AB LJ, Weinreb RN. Circardian change in intraocular pressure. Berlin: Springer-Verlag; 2009.
Barkana Y AS, Liebmann J, Tello C, Robert Ritch R. Clinical utility of intraocular pressure monitoring outside of normal office hours in patients with glaucoma. Arch Ophthalmol. 2006;124:793-7.
De Moraes C.G.V, Juthani V.J, Liebmann J.M, Teng C.C, Tello C, Susanna Jr R, Ritch R. Risk Factors for Visual Field Progression in Treated Glaucoma. Arch Ophthalmol 2011;129:562-8.
Kenneth Schwartza K, Budenzb D. Current management of glaucoma. Curr Opin Ophthalmol. 2004;15:119-26.
Leske M.C, Heijl A, Hyman L, Bengtsson B, Dong L, Yang Z,. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology 2007;114:1965-72.
Khouri A.S, Lama P.J, Fecthner R.D. Glaucoma medical therapy principles and management. new york: Oxford university press; 2008.
Zimmermant T.J, Bauman J.D, Hetherington J, . Side effects of timolol. Surv of ophthalmology. 1983;28 243-9.
Chiang, Ho J I, Chen J.C. Pharmacokinetics and intraocular pressure lowering effect of timolol preparations in rabbit eyes. Journal of ocular pharmacology and therapeutics 1996;12:471-80.
Dickstein K, Aarsland T. Comparison of the effects of aqueous and gellan ophthalmic timolol on peak exercise performance in middle aged men. Am J Ophthalmol 1996;121:367-71.
Hellberg MR, Verney L, Salle VL, Mclaughlin MA,. Sharif NA, Desantis L, Dean TR,. Zinke PW. Preclinical efficacy of Travoprost, a potent and selective FP prostaglandin receptor agonist. J Ocul pharmacol and ther 2001;17.
Toris CB, Zhan G, Fan S, Dickerson JE, Landry TA, Bergamini MV, Camras CB. Effects of Travoprost on Aqueous Humor Dynamics in Patients With Elevated Intraocular Pressure. J Glaucoma. 2007;16:189-95.
Toris CB. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol 2008;53:107-20.
Netland PA. Travoprost Study Group: Response to travoprost in black and non black patients with open angle glaucoma or ocular hypertension. Adv Ther. 2003;20:149-63.
Goldberg I, Cunha-Vaz JC, Jakobsen JE, Nordmann JP, Trost E, Sullivan K. Comparison of topical Travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. Journal of Glaucoma. 2001;10:414-22.
Stewart WC, Stewart JA, Nelson LA, Kruft B. Mean Standart Deviation for common glaucoma treatments. Acta Ophthalmol. 2009;87(1):112-4.
Lichter PR. Expectations from clinical trials results of the early manifest glaucoma trial. Arch Ophthalmol 2002;120:1371-2.
Martinez-Bello C CB, Nicolela MT. Intraocular pressure and progression of glaucomatous visual field loss. Am J Ophthalmol. 2000;129:302-8.
Medeiros F.A WRA, Zangwill L.M, Alencar L.M, Sample P.A, Vasile C, Bowd.C. Long-term Intraocular Pressure Fluctuations and Risk of Conversion from Ocular Hypertension to Glaucoma. Ophthalmology. 2008;115:934-40.
Caprioli J, Coleman. Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressure in the anvanced glaucoma intervention study. ophthalmology. 2008;115:1123-9.
Lee PP, Walt WJ, Rossenblatt LC, Siegartel LR, Stern LS. Association between intraocular pressure variation and glaucoma progression : data from a united states chart review. Am J Ophthalmol. 2007;144:901-7.
Nomura Y.Nakakura S. Effect of travoprost on 24-hour intraocular pressure in normal tension glaucoma. Clinical Opthalmology. 2010;4:643-7.
Dubiner HB., Noecker R,. Sustained intraocular pressure reduction throughout the day with travoprost ophthalmic solution 0.004%. Clinical Ophthalmology 2012;6:525-31.
Sit AJ, Weinreb NR, Jonathan G. Crowston GJ, Daniel F. Kripke DF, Liu JHK. Sustained effect of travoprost on diurnal and nocturnal intraocular pressure. Am J Ophthalmol. 2006;141:1131-3.
Larsson LI. Intraocular Pressure over 24 Hours after Repeated Administration of Latanoprost 0.005% or Timolol Gel-forming Solution 0.5% in Patients with Ocular Hypertension. ophthalmology. 2001;108:1439-44.
Konstas A.G.P, Mantziris DA, Cate EA, Stewart W.C. Effect timolol on the diurnal intraocular pressure in exfoliation and primary open angle glaucoma. Arch Ophthalmol. 1997;115:975-9.
Orzalesi N, Rossetti L, Invernizzi T, Bottoli A, Autelitano A. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sc. 2000;41:2566-73.
Konstas AGP, Quaranta L, Mikropoulos D.G,Nasr M.B, Russo A, Jaffee H.A,Stewart J, Stewart W.C. Peak intraocular pressure and glaucomatous progression in primary open-angle glaucoma. J Ocul Pharmacol Ther. 2012;28.
Wilensky JT, Gieser DK, Mori MT. Self tonometry to manage patients with glaucoma Am J Ophthalmol. 1987;105:1072-5.
Authors
Susetyo, P. B., Oktariana, V. D., Supiandi, E., & Prihartono, J. (2016). A Comparison 24 Hour Intraocular Pressures Between Travoprost 0.004% and Timolol Gel 0.1% on Controlled Primary Open Angle Glaucoma. Ophthalmologica Indonesiana, 41(2). https://doi.org/10.35749/journal.v41i2.27
Copyright and license info is not available
Article Details
How to Cite
Susetyo, P. B., Oktariana, V. D., Supiandi, E., & Prihartono, J. (2016). A Comparison 24 Hour Intraocular Pressures Between Travoprost 0.004% and Timolol Gel 0.1% on Controlled Primary Open Angle Glaucoma. Ophthalmologica Indonesiana, 41(2). https://doi.org/10.35749/journal.v41i2.27